Leerink starts coverage on Boston Scientific and Medtronic with bullish ratings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise by about $1/bbl on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
- Micron Technology (MU) Tops Q4 EPS by $2.26, Offers Guidance
Mizuho survey highlights upside in this MedTech stock
June 17, 2025 3:00 PM EDTThe renal denervation (RDN) platform could drive transformational growth for one medtech firm, according to a new Mizuho survey of cardiologists treating drug-resistant hypertension.
The analysts upgraded their outlook for Medtronic (NYSE: MDT) after results indicated strong enthusiasm for RDN and a clear lead for Medtronics Symplicity Spyral System over rival Recor Medical.
We conducted a snap poll... More
